OrbusNeich
 | |
| Company type | Public |
|---|---|
| HKEX: 6929 | |
| Industry | Medical devices |
| Founded | 2000 |
| Founder | Teddy Chien |
| Headquarters | Hong Kong |
Key people | David Chien (Chairman, Executive Director and Chief Executive Officer), Denise Lau (Executive Director and Chief Operating Officer), and Jason Chen (Executive Director, Chief Financial Officer and Company Secretary) |
| Products | Conventional and specialty catheters, drug eluting stents and drug coated balloons, imaging, and lithotripsy for coronary and peripheral intervention |
Number of employees | 1,300+ |
| Website | orbusneich |
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, OrbusNeich has developed world-leading proprietary technologies.
OrbusNeich is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 6929.
History
Founder – Mr. Teddy Chien
For over half a century, Mr. Teddy Chien worked with the medical community in various capacities at pharmaceutical and medical device companies. In 1970s to 1990s, he launched Cordis Neich and served as the sole distributor of Cordis Corporation for cardiology products such as balloon catheters and pacemakers in the APAC region. He gained substantial expertise and built a robust sales distribution network within the cardiovascular field throughout APAC. After Cordis Corporation and the assets of Cordis Neich were acquired by Johnson & Johnson in 1996, Mr. Chien founded Neich Medical (the former name of OrbusNeich) in 2000 to focus on the development and manufacturing of endovascular interventional devices.
Mr. Teddy Chien also established the Chien Foundation, a charitable organization dedicated to training young interventional cardiologists and advancing cardiovascular research. The foundation provides resources and opportunities for physicians in Asia to learn cutting-edge techniques, reflecting his belief of raising the standard of healthcare in the region.
The Founding of Neich Medical
Headquartered in Hong Kong, China, Neich Medical was founded in 2000 by Mr. Teddy Chien. In 2001, its main manufacturing facility in Shenzhen, China, began operations for the research and development of interventional medical devices, including balloon catheters. It received the first regulatory approval for its balloon catheter from PMDA in September in 2001.
In 2005, Neich Medical continued its international expansion by acquiring Orbus Medical Technologies Inc., a U.S. company and changed its name to OrbusNeich Medical. This acquisition expanded its research and development capacity to the United States, as well as its production and sales capabilities to Europe.
Rapid Growth of OrbusNeich
In 2016, Mr. David Chien became Chairman and Chief Executive Officer and redefined the business strategies to be more aggressive. Building on a strong presence in Asia and Europe, OrbusNeich entered the U.S. market in 2017, and since then, several products have been successfully launched, resulting in robust growth in market share.
In 2020, the company acquired its Swiss distributor to further strengthen market penetration in Europe. In addition to PCI/PTA balloons and coronary stent products, OrbusNeich is actively expanding into structural heart disease areas. In the same year, a joint venture was formed with the European partner, P&F Product & Features GmbH, to focus on the sales and development of structural heart products.
To support the company’s growth, over US$200 million was raised from well-known institutional investors in 2021. In 2022, OrbusNeich was successfully listed on the Main Board of the Hong Kong Stock Exchange, becoming the first and only Hong Kong Main Board-listed medical device company headquartered in the Hong Kong Science Park, raising about HK$480 million through an IPO.
In 2023, OrbusNeich acquired eucatech AG (Germany), PT Revass (Indonesia), and SJ Medicare (South Korea) to enrich its product offerings and further strengthen its sales network. The following year, a high-capacity logistics center was launched in the Netherlands. In 2025, OrbusNeich also acquired Taiwan Rich Medical to enhance the direct sales network in Taiwan.
Products
As of December 31, 2024, OrbusNeich owns more than 240 granted patents and published patent applications globally. Its diversified portfolio covers coronary, peripheral and structural heart diseases, improving lives in over 70 countries and regions worldwide.
Coronary Intervention
OrbusNeich offers a wide range of balloon catheters used for lesion preparation and post-dilatation, including:
OrbusNeich has built a reputation for its innovative lesion preparation technologies, especially scoring and non-compliant balloons that are critical in complex procedures. Their Scoreflex® series (including Scoreflex® NC and Scoreflex® TRIO) utilizes focused force technology, which allows for controlled and effective plaque modification, reducing complications like vessel dissection or uncontrolled balloon expansion. These balloons are often used in calcified, fibrotic, bifurcation, or ostial lesions, where conventional balloons may fail.
With the launch of the Sapphire® NC24, OrbusNeich entered a niche category of non-compliant balloons with ultra-high-rated burst pressure (RBP up to 24 atm). This makes it one of the few available options globally for operators needing extremely high-pressure post-dilation, particularly in heavily calcified arteries or under expanded stents. Despite its high-pressure capability, the balloon maintains precise control with minimal growth, enhancing safety and performance.
This diversity allows clinicians to select the optimal device for nearly any lesion type, from simple to the most complex. Unlike many competitors that focus only on drug-eluting technologies, OrbusNeich remains committed to advancing mechanical balloon performance—a reflection of real-world needs in interventional cardiology. Their engineering and material innovations, such as low-profile design, ultra-thin balloon materials, and high-pressure resistance, directly address operator demands.
OrbusNeich’s balloons are frequently used in highly complex PCI procedures, such as those involving chronic total occlusions (CTO), left main disease, and heavily calcified lesions. The devices’ deliverability (crossability, trackability, pushability and torquability) in complex anatomies are regarded as best-in-class by expert interventional cardiologists.
OrbusNeich’s balloon catheters are approved in over 70 countries and regions, including stringent regulatory markets such as Japan (PMDA), Europe (CE mark), the United States (FDA) and China (NMPA). They are widely adopted in major hospitals and catheter labs across Asia, Europe, the Middle East, and Latin America, contributing to their strong clinical reputation worldwide.
OrbusNeich offers one of the most complete portfolios of balloon catheters globally. Their lineup includes:
- Semi-compliant balloons (Sapphire® II PRO, Sapphire® 3): Ultra-low profile balloon catheter designed by OrbusNeich for navigating and treating complex coronary lesions, including chronic total occlusions (CTOs).
- Non-compliant balloons (Sapphire® NC, Sapphire® NC24): High-pressure non-compliant balloons, the latter with a rated burst pressure of up to 24 atm, intended for precise stent expansion.
- Scoring balloons (Scoreflex® NC, Scoreflex® TRIO): Focused force scoring balloons designed to modify calcified and fibrotic lesions using a dual or tri-element wire structure.
- Drug-coated balloons (SUPPORT CTM): Paclitaxel-coated balloon for the treatment of de novo lesions and restenosis.
- COMBO® Plus Coronary Stent is recognized as the world’s first dual therapy stent. It combines drug elution with endothelial progenitor cell (EPC) capture technology, intended to accelerate natural vessel healing and reduce the incidence of restenosis and late stent thrombosis.
- eucaLimusTM Coronary Stent System with Sirolimus Drug Coating, acquired from eucatech, this stent features a cobalt-chromium platform with a biodegradable PLGA polymer coating that elutes sirolimus. It offers a broad range of diameters (2.25–5.0 mm) and lengths (8–48 mm), catering to various vessel sizes.
- Teleport® (Teleport®, Teleport® Control, Teleport® XT) is engineered for optimal guidewire support and enhanced deliverability through tortuous or calcified anatomy in complex percutaneous coronary interventions (PCI).
- Xtenza® (marketed as EZGuideTM in Japan) is a guide catheter extension system developed by OrbusNeich, designed to enhance support and facilitate device delivery during complex percutaneous coronary interventions (PCI).
In peripheral vascular applications, OrbusNeich provides products for angioplasty and plaque modification:
- JADE® series (JADE®Rx, JADE®OTW, JADE®2, JADE®PLUS) is a high-performance, non-compliant balloon designed for peripheral angioplasty procedures, including treatment of lower limb, arteriovenous fistula, and renal artery. Known for its ultra-low profile, high burst pressure, and wide size matrix, Jade® delivers precise dilatation and optimal crossability in challenging peripheral lesions. Its robust shaft design ensures excellent pushability and trackability, while maintaining controlled balloon growth for accurate lesion treatment.
- Scoreflex® PTA is a scoring balloon catheter engineered for controlled plaque modification in peripheral artery disease (PAD). Featuring OrbusNeich’s proprietary dual-wire focal scoring technology, Scoreflex® PTA delivers focused dilating force to fracture fibrotic and calcified lesions with reduced risk of vessel dissection. Its controlled scoring mechanism enhances luminal gain and facilitates effective stent deployment, especially in resistant or restenotic lesions.
- VITUSTM is a paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter designed for the treatment of peripheral artery disease (PAD), particularly in the femoropopliteal segment. Utilizing a proven paclitaxel-in-resin coating matrix, VITUSTM delivers effective anti-restenotic therapy directly to the vessel wall without the need for a permanent implant. It is engineered for consistent drug transfer, excellent lesion crossability, and optimal balloon performance, offering a safe and efficient solution for preventing restenosis in complex peripheral interventions.
- Teleport® (Teleport® Control) is engineered for optimal guidewire delivery and exchange, as well as contrast media injection during peripheral intervention.
OrbusNeich has expanded into structural heart therapies through a distribution and development partnership with P+F Products + Features GmbH. Product includes:
- TricValve® Transcatheter Bicaval Valves is designed for patients with severe tricuspid regurgitation not eligible for open-heart surgery.
Locations
OrbusNeich operates globally, with its corporate headquarters located in Hong Kong, China. Through a combination of direct sales and a distributor network, OrbusNeich's sales coverage extends to over 70 countries and regions worldwide. The company has a direct sales presence in 13 markets, including the Mainland of China, France, Germany, Hong Kong, Macau, Monaco, Indonesia, Japan, Malaysia, Singapore, Spain, Switzerland, and Taiwan, partnering with over 200 distributors worldwide. Key distributor markets include Czech Republic, India, Italy, Saudi Arabia, Slovakia, South Africa, United Kingdom, United States, and Vietnam.
The company's research and development team boasts over 25 years of product development experience, with R&D centers based in Shenzhen, China, and Tokyo, Japan. Manufacturing facilities are located in Shenzhen, China; Hoevelaken, the Netherlands; and Weil am Rhein, Germany, each adhering to rigorous international quality management systems.
Social responsibility
OrbusNeich hosts the Physician Exchange Program (PEP), which brings experienced doctors to other countries to exchange knowledge with local physicians and share skills and expertise through complex cases like CTOs. The Annual Scientific Congress and Exchange for Next Generation Interventionalists (ASCENT) is a tailored educational program designed to provide the next generation of interventionalists with learning opportunities from senior physicians with diverse expertise.
In addition to these initiatives, OrbusNeich “Community Wellbeing” program supports local communities by funding academic cardiovascular research, scholarships, sponsorships, and charity events. The program has been donated to various non-governmental organizations to support these initiatives and promote wellbeing. OrbusNeich successfully partners with different non-profit organizations in their efforts to organize community-focused initiatives.
External Links
- ^ (January 2010). "OrbusNeich, a company providing stent technology for the future." European Heart Journal.
- ^ S. Saito, HARMONEE Study, European Heart Journal, April 2018.
- ^ G. de Luca et al, REDUCE Study, EuroIntervention, August 2019.
- ^ L.S. Kerkmeijer et al. Catheterization & Cardiovascular Interventions, October 2020.
- ^ M. Haude et al., REMEDEE Trial, JACC: Cardiovascular Interventions, April 2013.
Official website (www.OrbusNeich.com)
Business data for OrbusNeich: